Allakos Inc.

NasdaqGS ALLK

Allakos Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 873.00 K

Allakos Inc. Net Cash Used Provided By Financing Activities is USD 873.00 K for the Trailing 12 Months (TTM) ending September 30, 2024, a -67.88% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Allakos Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 2.72 M, a -98.09% change year over year.
Allakos Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 142.56 M, a -49.84% change year over year.
Allakos Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 284.21 M, a 6,950.61% change year over year.
Allakos Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 4.03 M, a -98.94% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: ALLK

Allakos Inc.

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive
Employees	131
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Key trends

Past 5 years